Mergers and Acquisitions

Date: 2022-02-01

Type of information: Company acquisition

Acquired company: Genibet (Portugal)

Acquiring company: Recipharm (Sweden)

Amount: undisclosed


Recipharm, has announced the acquisition of GenIbet, a Portuguese CDMO, specialising in the manufacture of biological clinical trial material and novel modalities such as viral vectors, RNA and microbiome. The acquisition forms part of Recipharm’s strategy to grow in the Biologics market, with a particular focus on drug substance manufacturing of novel ATMPs. The deal will provide Recipharm with a platform from which to build its capabilities in new Biologics modalities, leveraging GenIbet’s expertise in viral vectors and vaccines.


GenIbet was founded as a spin-off of Ibet - Instituto de Biologia Experimental e Tecnológica - in 2006 and currently has around 70 employees. Its Portuguese facility is located in Oeiras, just 11 km from Recipharm's facility in Lisbon. GenIbet currently works with customer projects in the preclinical and Phase 1 stages and has a track record of developing novel production processes. Through its relationship with not-for-profit research organisation Ibet, the CDMO offers deep scientific expertise and novel solutions where no established production route exists.


Is general: Yes